COMP <GO>
NAMS vs SUPN // NET PROFIT MARGIN
NewAmsterdam Pharma Company N.V. (NASDAQ) VS. Supernus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: NAMS 1
— SUPN 8
▲ NET PROFIT MARGIN LEADER: SUPN
LAST: $19.56 (-2.49%) • MKT CAP: $2.34B
net-margins
-60.00%
LAST: $41.92 (+0.19%) • MKT CAP: $2.44B
net-margins
-5.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAMS VS. SUPN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NAMS | SUPN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 89.60% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -4.50% | -30.50 | SUPN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.96% | 1.89% | -7.85 | SUPN | /fcf-yield <GO> |
| Operating Margin | -60.00% | -8.70% | -51.30 | SUPN | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | -5.40% | -54.60 | SUPN | /net-margins <GO> |
| Revenue Growth (YoY) | -50.60% | 8.60% | -59.20 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.94 | 4.84 | +11.10 | NAMS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | SUPN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.4 | 51.1 | -11.70 | SUPN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.88 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 22.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.34B | $2.44B | -$103.1M | SUPN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NAMS REV | SUPN REV | NAMS GROSS % | SUPN GROSS % | NAMS FCF | SUPN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $22.5M | $719.0M | — | 89.6% | -$147.8M | $46.0M |
| FY 2024 | $45.6M | $661.8M | — | 88.2% | -$158.6M | $171.2M |
| FY 2023 | $14.1M | $607.5M | — | — | -$141.2M | $83.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAMS // BETA —
SUPN // BETA 0.88